Features Archives - Page 11 of 15

Features

Roche develops diabetes data platform

The Basel-based pharmaceutical company Roche has entered a cooperation agreement with the consultancy firm Accenture. The aim is to develop a data platform that connects…

clement09.08.2017

Features

Only two years after founding, IFM therapeutics gets sold for up to $2.3B to BMS

clement04.08.2017

Features

U.K. Proposes Post-Brexit Fund to Close Technology Gap With U.S.

clement03.08.2017

Cellestia Biotech Scientist taking sample from Petri dish

Features

Evotec acquires Aptuit

With its acquisition of Aptuit, the biotechnology company Evotec intends to strengthen its position as a leading provider of drug research and development services. Aptuit,…

clement02.08.2017

Features

The Startling History Behind Merck’s New Cancer Blockbuster

clement27.07.2017

Features

Interest from startups in the BaseLaunch healthcare accelerator exceeds expectations

More than 100 projects from Switzerland and abroad competed for a place in the BaselArea.swiss accelerator program for healthcare startups By the closing date of…

clement25.07.2017

Features

US FDA has approved a cancer treatment based on a common biomarker, as opposed to the location in the body where the tumour developed.

clement27.06.2017

Features

Versant carefully sets the stage for a $68M debut of a biotech player focused on synthetic lethality

clement22.06.2017

Features

“I want to turn innovative research into new drugs”, Interview with Dr. Michael Bauer, CEO of Cellestia

Each year some 250,000 patients develop a type of cancer because of faulty communication between cells. This malfunction occurs in what is known as the…

clement20.06.2017

Features

Medicxi unveils a $300M late-stage biotech fund with a transatlantic scope

clement15.06.2017

Features

Roche develops diabetes data platform

Only two years after founding, IFM therapeutics gets sold for up to $2.3B to BMS

U.K. Proposes Post-Brexit Fund to Close Technology Gap With U.S.

Evotec acquires Aptuit

The Startling History Behind Merck’s New Cancer Blockbuster

Interest from startups in the BaseLaunch healthcare accelerator exceeds expectations

US FDA has approved a cancer treatment based on a common biomarker, as opposed to the location in the body where the tumour developed.

Versant carefully sets the stage for a $68M debut of a biotech player focused on synthetic lethality

“I want to turn innovative research into new drugs”, Interview with Dr. Michael Bauer, CEO of Cellestia

Medicxi unveils a $300M late-stage biotech fund with a transatlantic scope

Useful links

Contact us

Sign up for our newsletter and event invitations

Follow us